6:39 PM
Feb 22, 2016
 |  BC Extra  |  Clinical News

OBI breast cancer therapy misses Phase II/III endpoint

OBI Pharma Inc. (TPEx:4174) said OBI-822/821 missed the primary endpoint of progression free survival (PFS) in a top-line analysis of its Phase II/III study to treat metastatic breast cancer. The company said the data showed a significant...

Read the full 175 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$50 USD
More Info >